Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
5.27
-0.05 (-0.94%)
At close: May 9, 2025, 4:00 PM
5.27
0.00 (0.00%)
After-hours: May 9, 2025, 4:00 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 131 employees as of September 30, 2024. The number of employees decreased by 14 or -9.66% compared to the previous year.
Employees
131
Change (1Y)
-14
Growth (1Y)
-9.66%
Revenue / Employee
$508,328
Profits / Employee
-$800,977
Market Cap
113.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ENTA News
- 4 weeks ago - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
- 7 weeks ago - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium - Business Wire
- 3 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - Business Wire
- 4 months ago - Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit - Business Wire
- 5 months ago - Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 5 months ago - Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - Business Wire